Goldman Sachs Gives Boston Scientific Corporation Price Target With Potential 5.88% Upside

Cesar Mills
May 19, 2017

If the $28.34 price target is reached, the company will be worth $2.56B more. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. Moreover, Sabby Management Llc has 3.21% invested in the company for 2.01 million shares. In order to reach an opinion and communicate the value and volatility of a covered security, analysts research public financial statements, listen in on conference calls and talk to managers and the customers of a company, typically in an attempt to capture the findings for a research report. It has outperformed by 1.06% the S&P500. On average, analysts forecast that Boston Scientific Co. will post $1.25 EPS for the current fiscal year. The Lower end of the earnings estimate is $0.3, while the higher end of the earnings estimate is $0.32. BSX's profit will be $427.61M for 21.36 P/E if the $0.31 EPS becomes a reality.

United States of America based company, Boston Scientific Corporation (BSX)'s latest closing price distance was at 11.18% from the average-price of 200 days while it maintained a distance from the 50 Day Moving Average at 4.66% and 1.67% compared with the 20 Day Moving Average.

The target price for Boston Scientific Corporation (BSX) is $29.32/share according to the consensus of analysts working on the stock, with an expected EPS of $0.31/share for the current quarter. Therefore 76% are positive.

Boston Scientific has a 52 week low of $19.67 and a 52 week high of $26.76 with a P/E ratio of 85.16 The company's market cap is now $0. (SRC) stock price distance from twenty day simple moving average slumped at -19.80% while its distance from fifty day simple moving average declined -26.24% along with -35.07% below distance from two hundred simple moving averages. Zacks Investment Research downgraded shares of Boston Scientific from a "hold" rating to a "sell" rating in a research report on Wednesday, April 5th. Oppenheimer maintained Boston Scientific Corporation (NYSE:BSX) rating on Monday, May 1. The firm earned "Overweight" rating on Friday, July 29 by JP Morgan. The stock of Boston Scientific Corporation (NYSE:BSX) earned "Strong Buy" rating by Raymond James on Monday, October 5. The Return on Investment (ROI) ratio of Boston Scientific Corporation (BSX) is 5.1 percent. The firm has "Buy" rating by Needham given on Monday, September 28. Goldman Sachs upgraded the stock to "Neutral" rating in Thursday, August 27 report. The firm has "Outperform" rating given on Friday, August 12 by Scotia Capital. The rating was initiated by Suntrust Robinson with "Buy" on Thursday, February 25.

Annual Dividend Yield of Boston Scientific Corporation (BSX) stands at 0%. Wedbush has "Neutral" rating and $25 target. Boston Scientific has a consensus rating of "Buy" and a consensus price target of $27.83.

Investors sentiment decreased to 0.84 in 2016 Q4. Capital World Investors increased its position in Boston Scientific by 2.9% in the third quarter. Fmr Ltd Co accumulated 171.60M shares or 0.5% of the stock.

Burnley vs West Ham 21 May 2017: EPL Preview and Predictions
West Ham United manager Slaven Bilic during the Premier League match at The London Stadium, London. He has a hip problem and has not played the last few games.

One Dead, 22 Injured After Speeding Car Hits Pedestrians In Times Square
White House Press Secretary Sean Spicer said US President Donald Trump "has been made aware" of the incident. He says the driver was "just mowing down people". "I don't think there was actually time for screaming".

Mike Huckabee calls Roger Ailes a 'genius'
Ailes reportedly fell, hit his head and was seriously bleeding eight days before he died, according to a Palm Beach police report. Sherman also tweeted out that , "A Fox News employee who'd been sexually harassed by Ailes said this morning, "Justice".

While looking at the SMA values of Boston Scientific Corporation (BSX), the 200 simple moving average (SMA) is considered a key indicator by traders and market analysts for determining the overall long-term trend.

Samlyn Capital Llc increased Amgen Inc (NASDAQ:AMGN) stake by 313,500 shares to 458,000 valued at $66.97 million in 2016Q4. Wells Fargo And Mn accumulated 0.06% or 8.09 million shares. Riverhead Capital Mngmt Limited Liability Company holds 0.28% or 209,833 shares in its portfolio.

Janus Capital Management Llc decreased Ecolab Inc (NYSE:ECL) stake by 96,965 shares to 612,760 valued at $71.83M in 2016Q4. Commonwealth Of Pennsylvania Pub School Empls Retrmt Sys holds 0.03% or 78,058 shares in its portfolio.

Boston Scientific Corporation's Quick Ratio shows the value of 0.6. The company was maintained on Tuesday, October 25 by RBC Capital Markets. Its down 0.28, from 1.12 in 2016Q3. The shares were sold at an average price of $24.84, for a total transaction of $120,026.88. The shares were sold at an average price of $24.55, for a total transaction of $1,940,554.75. Also, SVP David A. Pierce sold 3,417 shares of Boston Scientific stock in a transaction dated Monday, February 27th. $739,134 worth of stock was sold by Dawkins Keith D on Tuesday, February 28. The ROA ratio is calculated by comparing net income to average total assets, and is expressed as a percentage.

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The relative volume of the stock is 1.42, while its market cap is $36.37 Billion. The Firm offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

The price/earnings ratio (P/E) is 83.80 and the forward P/E ratio stands at 18.54. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg.

Other reports by GizPress

Discuss This Article